Simon Breitler, PhD

Simon Breitler, PhD

He previously served as Chief Operating Officer at eracal therapeutics which he co-founded and which was sold to Novo Nordisk for approx. EUR 250m in upfront and milestones in addition to royalty payments. Before that, led a team in preclinical chemistry, manufacturing, and control (CMC) department at Roche. Simon Breitler holds a Ph.D. in synthetic organic chemistry from ETH Zurich which was complemented with a fellowship at Harvard University.